SG Americas Securities LLC Purchases 14,207 Shares of Exelixis, Inc. $EXEL

SG Americas Securities LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 39.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,495 shares of the biotechnology company’s stock after buying an additional 14,207 shares during the quarter. SG Americas Securities LLC’s holdings in Exelixis were worth $2,166,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. RHS Financial LLC boosted its holdings in Exelixis by 2.4% during the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 293 shares during the period. Meeder Advisory Services Inc. lifted its position in shares of Exelixis by 5.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 298 shares during the last quarter. Cim LLC boosted its stake in Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after purchasing an additional 305 shares during the period. J.W. Cole Advisors Inc. boosted its stake in Exelixis by 6.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 329 shares during the period. Finally, Spire Wealth Management grew its holdings in Exelixis by 4.5% in the 4th quarter. Spire Wealth Management now owns 9,643 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 416 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EXEL. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Tuesday, May 19th. TD Cowen raised their price objective on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Stifel Nicolaus boosted their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Truist Financial cut shares of Exelixis from a “buy” rating to a “hold” rating and upped their target price for the company from $51.00 to $54.00 in a research note on Thursday, June 25th. Finally, Morgan Stanley restated a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $46.87.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the transaction, the executive vice president directly owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dana Aftab sold 43,451 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. This trade represents a 6.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is owned by insiders.

Exelixis Trading Down 0.8%

Shares of EXEL stock opened at $53.96 on Thursday. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $55.91. The company has a market capitalization of $13.56 billion, a P/E ratio of 17.93, a P/E/G ratio of 1.57 and a beta of 0.42. The stock has a 50 day moving average of $50.18 and a two-hundred day moving average of $45.80.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.Exelixis’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 earnings per share. Sell-side analysts predict that Exelixis, Inc. will post 3.16 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.